Blog

Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job

At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.

Over the last two years, the pandemic has opened a window into the fascinating challenges that lie at the intersection of science and technology - where scientists and technologists can work together to solve real-world problems and improve patients’ quality of life.  This is the world that we inhabit here at BenevolentAI, where we build tech in the service of science to discover new medicines with a higher probability of clinical success. 

Despite the challenges posed by the pandemic, we’ve continued to grow our team and have virtually hired and onboarded over 100 Benevolent People across our London and New York offices and Cambridge (UK) labs. These include talented AI and machine learning scientists, software engineers, informaticians, data scientists and designers, who work alongside drug discovery scientists, chemists and pharmacologists in highly collaborative, multidisciplinary teams. As Director of Talent and Development, candidates often ask me if they need the perfect blend of science and technology backgrounds in order to be successful at Benevolent. In reality, this couldn’t be further from the truth; in a field as complex as AI-driven drug discovery, no single discipline has all the answers. 

So, what sets someone up for success at Benevolent? To quote our Lead AI Scientist, Saee Palliwal, at our Women In Tech meetup; “There is no cookie-cutter of the perfect employee”. To solve previously unsolved problems we have to have diversity of thought. Each person brings valuable insights to the table, which is what makes BenevolentAI so special: there is no such thing as a ‘stupid question’ as we look at working collaboratively with others to make a difference.  The key to being successful at Benevolent, therefore, doesn't only lie in qualifications or experience. It's also found in a person’s curiosity, their openness to having their opinion challenged and their ability to communicate technical or complex concepts in a way that someone with a completely different background can understand. Certainly, in my time at BenevolentAI, I have worked alongside some of the kindest and most intelligent people I have ever had the privilege to meet - people who are always generous with their time and willing to listen, learn and share understanding.

After all, being at Benevolent means being a part of a community that cares about creating a great place to work, where we feel challenged and inspired by the work we do and the people we work with. Recently, we were featured in Sifted in the top 10 European unicorns for Employee Satisfaction and we are phenomenally proud of our Glassdoor rating of 4.7/5, which reflects our commitment to nurturing community and culture.

Over the coming months, my team will be leading our extensive hiring efforts across drug discovery, tech and business operations - you can browse our jobs here for more information. There has never been a more exciting time to join BenevolentAI, with remarkable platform, pipeline and partnership milestones including; identifying a leading treatment for COVID-19, which is now approved by the FDA; commencing the first clinical trial for our in-house Atopic Dermatitis treatment; a successful ongoing partnership with AstraZeneca and, finally; a pro-bono research effort conducted in collaboration with the Institute of Cancer Research. The latter saw our team successfully identify a new drug combination for children with a deadly form of childhood brain cancer that has not seen survival rates improve for more than half a century. 

When you step into our London office, you’re greeted by a neon sign that reads ‘Because it Matters’. The sign is a glowing reminder of our purpose; to help patients live longer, happier lives. This common purpose drives everything we do and unites us behind a common goal, reminding us of the collective impact behind every hiring decision, every experiment and every piece of code. Every milestone and every success is something we all share, no matter where we sit in the business. We do our work ‘because it matters’, and it’s this scale and scope for lasting positive impact that makes working at BenevolentAI so rewarding - and there’s still plenty of work to be done. 

We are hiring for multiple roles across our London, Cambridge (UK) and New York locations. If you can’t find a role that fits, you can add your details to one of our Talent Pools - just pick the talent pool that fits your profile the best, and we’ll be in touch when there’s a good match with your skills and background.

Yasmina Rahiman

Director of People and Talent
More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022